SunRock Biopharma S.L / Pharmaceutical

SunRock is developing therapeutic antibodies against novel targets in cancer

SunRock is a biopharmaceutical company incorporated in 2014 with the objective of developing and commercializing new oncological therapies directed against the new target CCR9 and its associates.

SunRock Biopharma develops therapeutic human antibodies directed against the Chemokine Receptor 9 (CCR9) for the treatment of acute lymphoblastic leukemia and aggressive lung, ovary, prostate, breast and melanoma carcinomas.

2015

Foundation year

4

Employees

Business areas

• Cancer therapy

Lines of business

• Research and development of therapeutic antibodies against cancer

Products / services

• Therapeutic antibodies

Main interests in foreign markets

Investors and collaborators

Patents

• PCT/EP2014/075578 - « Antibodies against CCR9 and applications thereof. »

• EP13382469.8 - « Antibodies against CCR9 and applications thereof. »

Contact person:

Juan Buela (Manager)

Address:

Edificio CiMUS. Campus Vida, Av. Barcelona,
s/n, 15782 Santiago de Compostela, La Coruña

Phone:

(+34) 881 815 390

Email:

info@sunrockbiopharma.com

Website:

www.sunrockbiopharma.com

Contact SunRock Biopharma S.L